


The Use of Citrate as an Anticoagulant for Continuous Renal Replacement Therapy

Dr David Stanley, Consultant
Russell's Hall Hospital, Dudley

Tuesday 28th April 2015



Declaration

- Attended Gambro (now Baxter) user group meeting Feb 2015
- Free lunch & some nice biscuits



Introduction

- Why citrate?
- How citrate is used
- Our experience at RHH



Why Citrate at RHH?

- Needed new filters
- Wanted the option of using citrate



Ideal Anticoagulant

- During RRT, to prevent clotting in the extracorporeal circuit anticoagulation is needed
- Ideally this anticoagulant should be
 - Regional
 - Reversible/short half-life
 - Free from side effects
 - User friendly



Citrate vs Heparin

Citrate

- Regional coagulation
- No bleeding risk
- No extra-platelet effect
- Additional filter fluid; citrate
- Citrate toxicity

Heparin

- Systemic anticoagulation
- Bleeding risk
- Thrombocytopenia, particularly Type 2 HIT
- Standard filter fluids



Why Citrate?

- Only the filter is anti-coagulated;
 - ideal for bleeding patient (trauma, intracerebral haemorrhage)
 - returning from Theatre etc.
- Invasive procedures (lines, tracheostomies, surgery etc.) can be done without stopping CRRT; increases effectiveness of therapy whilst saving laborious & expensive set changes, blood loss
- Less circuit downtime – higher dose of therapy delivered
- Heparin needs monitoring & can be difficult to get right (NB patients prothrombotic despite apparent anticoagulation cf TEG)




Thrombocytopenia

- Patients requiring RRT are the most septic & so often their platelets are already low
- Thrombocytopenia; Type 1 (common, day 4-5 but usually mild, transient)
- Type 2; uncommon/rare immunological reaction, causes venous & arterial clots, not easy to diagnose (immunology to Bristol??) which takes time.
- Heparin then Cld for that patient lifelong with many potential implications.




How Citrate Works

Coagulation cascade



Mode of Action I

- Citrate chelates ionised Calcium (and Magnesium)



Citrate Dose

- Clotting does not occur with ionised calcium level in the extracorporeal circuit 0.25 - 0.35 mmol/L (in reality upper limit \sim 0.5mmol/L)
- Achieved by a concentration of citrate; 3 - 4 mmol/L blood
- Prismaflex administers citrate solution into the circuit at a dose to maintain circuit ionised calcium levels between 0.25 and 0.35 mmol/L post filter – default starting dose 3.00 mmol/L blood




Calcium Distribution

In the blood




In the circuit



Mode of action II

- Citrate is metabolised in liver, skeletal muscle and kidney into bicarbonate releasing the chelated calcium




Key Point

- Citrate anti-coagulation is in effect like giving Bicarbonate



Circuit Set-Up



Flow Settings

Actual Body Weight (Kg)	Blood flow, ml/min.	Dialysate, ml/hr.	Replacement, ml/hr.	Resulting Treatment Dose
60	110	1100	400	37mls/Kg/hr
70	120	1200	500	35mls/kg/hr
80	130	1300	500	33mls/kg/hr
90	140	1400	500	31mls/kg/hr
100	150	1500	600	31mls/kg/hr
110	160	1600	700	30mls/kg/hr
120	170	1700	800	30mls/kg/hr
130	180	1800	1000	30mls/kg/hr



Cautions with Citrate

- Not metabolised in
 - fulminant hepatic failure
 - cirrhosis
 - liver blood flow very poor
 - conditions associated with severely reduced muscle perfusion
- Citrate accumulation results in rising measured blood total calcium
 - watch total:ionised calcium ratio approaching 2.5
 - Rising calcium compensation



Citrate Accumulation

- Due to large amounts of citrate being infused more rapidly than they can be cleared by either dialysis or metabolic pathways
- Citrate circulates in plasma mainly bound to calcium.
- Accumulation of citrate causes progressive ionised hypocalcemia (<0.95 mmol/L) and may be associated with metabolic acidosis or metabolic alkalosis, depending on citrate metabolism and infusion rate
- Clinical manifestations include tetany, seizures, hypotension and cardiac dysrhythmias



Characteristics of citrate accumulation

- Decreasing iCa^{++}
- Increasing calcium replacement requirement
- Increasing TotCa / iCa^{++} ratio (>2.5) and TotCa - iCa^{++} gap
- Hypercalcemia



Citrate Disadvantages

- Initial educational work
- Requires close monitoring of calcium, pH and electrolytes
- Metabolic complications
- Citrate toxicity if citrate not adequately metabolised
- Fluid costs



Monitoring Regime

1.2.13 Calcium Monitoring & Adjusting Citrate (Prismocitrate)

Monitoring of Anticoagulation	After Onset or Any Change in Flow Rates			If Flow Rates Unchanged		
Post Filter Ionised Calcium (Blood gas from circuit) Target; 0.25 - 0.50 mmol/L	1 hour	4 Hours	6 Hours Then every 6 hours			
Patient Ionised Calcium (ABG from patient) Target: 0.99 - 1.20 mmol/L	1 hour	4 Hours	6 Hours Then every 6 hours			
Patient Total Calcium (Laboratory Biochemistry)	Once a day from laboratory Biochemistry result					
Calcium Ratio (Patient Total Calcium : Ionised Calcium ratio) Target: < 2.5mmol/L	Ratio checked daily & calculated. Displayed on ICCA in 'Renal Replacement' <u>Flowsheet</u> . If ratio > 2.5; inform medical staff immediately					

RHH Data 01/04/14-31/03/15

RHH Data


- Retrospective analysis of ICU EPR
- 41/326 (8%) patients received RRT
- 2 IHD
- 1 patient data missing
- 39 patients analysed
- Probably underestimated number of filters used, if no gap in the hourly flowsheet
- Reason for filter stopping very subjective




File Edit View Patient/Chart Document Tools Window Help Dr David Stanley Cons. GMC 4278904												
Bed 8												
Patient Demographics Flowsheets Laboratory Results Medical Notes Orders To do list Nursing Notes Communication Sheets AHP Notes Forms Imported Documents												
Flowsheet		19/01/2015	05:00	06:00	07:00	08:00	09:00	10:00	11:00	12:00	13:00	14:00
[Auto-chart every q1hr]												
+ Temp1 Central Site		36.5/CO	36.5/CO	36.4/CO	36.5/	36.4/	35.8/	35.6/	35.9/	36.3/	36.3/	
+ Temp2 Other Site												
Heated Wires +/- Bair Hugger on?						Yes	Yes	Yes	Yes	Yes	Yes	
BE(B) - ABG			-1.3		-2			-1.9				
H+ - ABG			49		60			47				
Lactate - ABG [0.5-2.0]			2.29		1.8			1.9				
Na+ - ABG [135-145]			132		135			132.1				
K+ - ABG [3.50-5.30]			5.11		4.18			5.7				
Urea [2.5 - 7.5]			8.5									
Creatinine [60 - 115]			200									
Ca++ - ABG [1.13-1.32]			1.14					1.07				
Calcium Total [2.1 - 2.6]			2.27									
Total Ca/Ca++ Ratio			2									
Cl- ABG [98-106]			101		101			102				
HCO3-act - ABG			25.3		25.8			24.2				
Phosphate [0.8 - 1.4]			1.93									
Magnesium [0.70 - 0.95]			0.77									
Platelets [140 - 400]			49									
Filtration Mode		CVVHDF	CVVHDF	CVVHDF	CVVHDF	CVVHDF	CVVHDF	CVVHDF	CVVHDF	CVVHDF	CVVHDF	CVVHDF
Anti-Coagulation		Citrate	Citrate	Citrate	Citrate	Citrate	Citrate	Citrate	Citrate	Citrate	Citrate	Citrate
BLOOD (Pump Speed)		150	150	150	150	150	150	150	150	150	150	150
Pre Blood Pump		1500	1500	1500	1500	1500	1500	1500	1500	1500	1500	1500
Dialysate (PrismOcal)		1500	1500	1500	1500	1500	1500	1500	1500	1500	1500	1500
Replacement (Phoxilium)		600	600	600	600	600	600	600	600	600	600	600
Fluid Removal Target		10	10	50	50	50	50	50	100	100	100	100
Effluent Rate		3632	3632	3672	3672	3672	3672	3672	3723	3723	3723	3723
Urine:Catheter		0	5	15	0	0	20	0	0	0	0	(60)
TMP		83	84	88	94	48	89	90	88	98	96	96
Access Pressure		-75	-79	-81	-81	-75	-77	-88	-81	-83	-80	-80
Filter Pressure		154	169	163	162	135	137	123	123	122	124	124
Effluent Pressure		32	44	36	33	31	8	-9	-14	-11	-7	-7
Return Pressure		109	120	115	118	86	90	76	75	79	79	79


Anticoagulation

Patients (38)




Sets (80)





Duration using Citrate





Filter Duration without Citrate (hrs)

- Elective (treatment withdrawn); 8, 17, 84
- Clogged; 14, 15, 41
- Unknown; 16, 26, 29, 53, 55, 90



Reason for stopping



Citrate Accumulation

- After 46 & then 64 hours in the same patient with liver failure
- Detected by Total:Ionised Ca 2.5
- No adverse features
- Self-resolved with time



Costs

- Fluid costs for a 90kg patient on a standard regime £210/day
- Calcium gluconate £37
- £28,431 in 2014-15 on renal fluids



Pros

- Removed all the worries of the bleeding patient
- Reassurance that thromocytopenia is not due to anticoagulant
- Citrate toxicity not a problem (advisory built in to the EPR)
- Anecdotally sets lasting longer; retrospective data actually hard to interpret (real reason filter stopped?)



Cons

- Big mindshift out of our comfort zone
- Staff training;
 - Internally
 - Gambro
 - Consultant M&M
- Junior medical staff no knowledge
- As with all new treatment modalities a big learning curve
- Patients under/overtreated/reluctance to change prescription
- Very shutdown / poorly perfused acidotic patients are challenging



Acknowledgements

- Baxter for slides 10,11,13,14
- Dr Borgstom, Kalmar Hospital, Sweden for the schematic on slide used for 16

References

- Monchi M. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. *Intensive Care Med.* 2004 Feb;30(2):260-5.
- Longer circuit life; 70 vs 41
- Oudemans-van Straaten HM et al. Citrate anticoagulation for continuous venovenous hemofiltration. *Crit Care Med.* 2009 Feb;37(2):545-52.
- Vs nadroparin; Less bleeding, lower mortality, less metabolic alkalosis. Circuit lives similar.
- Oudemans-van Straaten HM et al. Citrate for continuous renal replacement therapy: safer, better and cheaper. *Critical Care* 2014, 18:143 (19 May 2014)
- Ronco C et al. Renal replacement therapy in acute kidney injury: controversy and consensus. *Critical Care* 2015 19:146
- Gattas D et al. A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. *Critical Care Medicine* 2015 (accessed 26/4/15; not in print yet)
- Median duration 39 vs 23 hrs, reduced complications, no difference in outcomes; mortality, LoS, RBC transfusion



“In this citrus soaking sunshine I don’t care”

- Brown I, Squire J. *Bye, Bye Badman, Track 5, The Stone Roses, The Stone Roses. Silvertone Records 1989*



